Seeking Alpha

Gilead Sciences (GILD +5.3%) pops after saying it plans to initiate a Phase III trial to...

Gilead Sciences (GILD +5.3%) pops after saying it plans to initiate a Phase III trial to evaluate a combination of sofosbuvir and ledipasvir in patients with hepatitis C. Phase II results suggest "once-daily oral therapy with [the combo] may have the potential to cure most genotype 1 HCV infected patients with a remarkably short treatment duration," says Dr. Eric Lawitz, the study's principal investigator. Some have suggested a combination of sofosbuvir and BMY's daclatasvir is preferable, as both are active in genotype 3 HCV whereas ledipasvir may only be effective against genotype 1. (Related: I, II, III)
From other sites
Comments (5)
  • zorro2828
    , contributor
    Comments (602) | Send Message
     
    they declare tonight.. I am expecting great numbers and this company has rewarded those with patience and verve.. bought more today
    2 May 2013, 10:31 AM Reply Like
  • sprasad03
    , contributor
    Comments (75) | Send Message
     
    I bought more on all the dips to $50.00, looking for this to explode today.
    2 May 2013, 11:02 AM Reply Like
  • Estein0000
    , contributor
    Comments (2) | Send Message
     
    Gilead needs to start up another late stage study with BMY's
    Daclatasvar which is superior in combination with sofosbufir for genotype 2 and 3.
    I surmise that it's distasteful for gilead to work with BMY and split the profits
    for the sake of medicine instead of developing an inferior product just to maximize their own profits.
    2 May 2013, 11:03 AM Reply Like
  • markmt1988
    , contributor
    Comments (2) | Send Message
     
    From my understanding they have their own combination that they can get approved more rapidly. Ledipasvir (GS-5885) is their Daclatasvir. At first many where displeased with Gilead's choice to discontinue research with BMY, but that choice has proved to be the right one. I believe Sofosbuvir/Ledipasvir single pill regimen will be the standard treatment for Hepatitis infected patients. Sofosbuvir has definitely turned out to be Gileads golden ticket.
    2 May 2013, 12:07 PM Reply Like
  • markmt1988
    , contributor
    Comments (2) | Send Message
     
    From my understanding they have their own combination that they can get approved more rapidly. Ledipasvir (GS-5885) is their Daclatasvir. At first many where displeased with Gilead's choice to discontinue research with BMY, but that choice has proved to be the right one. I believe Sofosbuvir/Ledipasvir single pill regimen will be the standard treatment for Hepatitis infected patients. Sofosbuvir has definitely turned out to be Gileads golden ticket.
    2 May 2013, 12:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector